Italian HIFU guidance reveals “medtech’s biggest problem”
This article was originally published in Clinica
A lack of evidence is the medtech sector’s “biggest problem” when it comes to assessing the comparative clinical effectiveness of surgical interventions, Italy’s health services policy body, Agenas, has said in explaining draft guidelines issued for consultation on the use of high-intensity focused ultrasound (HIFU) to treat certain prostate cancers.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.